Formulation Services

Analytical Services

Company Overview 

News & Media

Join Our Team

Unlocking the potential
of transformative medicines
for our customers.

Contact Us


 

the preferred CDMO for pharma and biotech companies

 


Combo-Webinar-On-Demand-Syringe-LI-1200x628 (1)

 
Alcami-EM
 

Lab Open House

+0

Years of Experience

+0

Investigational New Drug Filings

+0

Product Launches

+0

Molecules Supported Annually

ALCAMI TO PROVIDE ANALYTICAL SUPPORT SERVICES FOR NOVAVAX’ COVID-19 VACCINE CANDIDATE

DURHAM, N.C. – November 16, 2021 – Alcami, a leading United States-based contract development and manufacturing organization (CDMO), announced today that they have signed a master laboratory services agreement with Novavax, a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases. With the execution of the agreement, Novavax has immediately secured full-time equivalent (FTE) resources to provide analytical testing support for its recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-M™ adjuvant. 

PHARMATHER ENGAGES ALCAMI FOR CLINICAL AND COMMERCIAL MANUFACTURING OF NOVEL KETAMINE PRODUCTS

TORONTO, October 19, 2021 -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, announces it has entered into an agreement with Alcami Corporation (“Alcami”), a global pharmaceutical contract development and manufacturing organization (CDMO) with extensive experience in cGMP sterile fill-finish products and handling of controlled substances, for the clinical and commercial manufacturing of the Company’s proprietary ketamine products.  

ALCAMI EXPANDS PARENTERAL OPERATIONS WITH ADDITIONAL INVESTMENT

CHARLESTON, S.C. – September 29, 2021 - Alcami, a leading United States-based contract development and manufacturing organization (CDMO), announced today an additional $31 million investment to expand its sterile development and manufacturing operation in Charleston, SC. The investment will add a second production line consisting of a vial washer and depyrogenation tunnel, with an isolator filling line containing two lyophilizers, substantially increasing fill-finish and lyophilization capacity. In addition to the new production line, investment has been made in enhanced semi-automated visual inspection equipment to support the additional manufacturing capacity. The new equipment will be qualified and ready for contract cGMP manufacturing in 2022.